louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02442622: Effectiveness of Astym Treatment For de Quervain's Tenosynovitis
Official title: Effectiveness of Astym Treatment For de Quervain's Tenosynovitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: de Quervain's Disease
Keywords: de Quervain's disease
de Quervain's tenosynovitis.
ASTYM
de Quervain's treatment
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
First posted: 2015-05-13
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To determine if the addition of Astym treatment to traditional therapy produces a more positive outcome then traditional therapy alone for the treatment of de Quervain's tenosynvitis. Two groups will be examined with one group receiving traditional therapy and the other group receiving traditional therapy in addition to Astym treatment protocol.


Eligibility criteria: Inclusion Criteria:

i. Positive Finkelstein's test: The client will report pain over the first compartment of the extensor retinaculum when the thumb is tucked in the hand and deviated ulnarly.

ii. Persistent symptoms for \>3 wks which have not resolved after an additional 3 weeks of splinting

iii. A diagnosis by a physician of "de Quervain's", "fist compartment tenosynovitis", or "radial styloid tenosynovitis"

iv. Patients must agree and comply to a predetermined splinting regimen

Exclusion Criteria:

i. History of cortical steroid injection to affected wrist and/or thumb

ii. History of previous wrist trauma to affected limb

iii. Comorbidity such as carpal tunnel syndrome (CTS), radial tunnel syndrome, osteoarthritis, rheumatoid arthritis, auto-immune disease or inflammatory conditions, lateral epicondylitis or tendinopathies

iv. Clotting deficits

v. Positive Cozen's sign which would indicate intersection syndrome

vi. Post-partum mothers \<6 months and pregnant women

Primary outcomes:
measure: Numeric Rating Scale for Pain
timeFrame: 4.5 months
Secondary outcomes:
measure: Sequential Occupational Dexterity Assessment (SODA) Score
timeFrame: 1.5 months
measure: Quick Dash Score
timeFrame: 4.5 months
Other outcomes:
Locations:
city: New York
country: United States
facility: NYU Langone Medical Center, Center for Musculoskeletal Care
state: New York
Study officials:
affiliation: NYU Langone Medical Center
name: Stephen VanLew, PhD, OTR/L
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01376622: Changes in Pituitary Iron and Volume With Deferasirox
Official title: Changes in Pituitary Iron and Volume With Deferasirox in Transfusional Iron Overload
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Iron Overload
Lead sponsor: Children's Hospital Los Angeles
Sponsor class: OTHER
Collaborators: name: Novartis Pharmaceuticals
First posted: 2011-06-20
Enrollment: 130
Sex: ALL
Minimum age (years): 2
Maximum age (years): 25
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Transfusion Dependent Anemia

Brief summary: Despite continuing advances in iron chelation therapy, iron toxicity of endocrine glands, particularly the pituitary gland, remains common in patients with transfusion dependent anemias. We would like to establish accurate population norms of pituitary R2 and volume and understand the progression of pituitary iron in transfused patients on Deferasirox.


Eligibility criteria: Inclusion Criteria:

* Currently on chronic transfusion therapy.
* Duration of chronic transfusion \>1 year.
* Age 2 to 25 years
* On deferasirox monotherapy for the duration of the study.
* Informed consent from legal guardian and/or patient.
* On deferasirox for a minimum of 3 months at start of study.

Exclusion Criteria:

* Sickle cell disease or sickle-beta zero genotype.
* Combination of deferasirox and another iron chelator.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Children's Hospital Los Angeles
state: California
Study officials:
affiliation: Children's Hospital Los Angeles
name: John C Wood, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Wood JC, Noetzl L, Hyderi A, Joukar M, Coates T, Mittelman S. Predicting pituitary iron and endocrine dysfunction. Ann N Y Acad Sci. 2010 Aug;1202:123-8. doi: 10.1111/j.1749-6632.2010.05545.x.
Clinical trial NCT00647322: The Impact of Reducing Overtreatment on Quality of Life in Children With Refractory Epilepsy
Official title: The Impact of Reducing Overtreatment on Quality of Life in Children With Refractory Epilepsy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Intractable Epilepsy
Keywords: Intractable epilepsy, Drug Reduction, Antiepileptic medication
Lead sponsor: Institute of Child Health
Sponsor class: OTHER
First posted: 2008-03-31
Enrollment: 64
Sex: ALL
Minimum age (years): 6
Maximum age (years): 21
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: The primary aim of the study is to determine the effect of reducing the number and/or dose of anti epileptic drugs on an individual's quality of life and seizure control in people with difficult to control epilepsy and who are on polytherapy.

This is a randomised trial so children will be divided into two groups, with reduction of anti epileptic drugs in the first group (withdrawal group) and no change to their medications in the second (control group). Irrespective of the group the child is assigned to (withdrawal group or control group), we will ask parents to complete several questionnaires on 2 occasions: the first time will be immediately after the child enters the study (i.e. baseline assessment), and a second and last one will be 6 months after entering the study (i.e. follow-up assessment). These questionnaires aim to "quantify" aspects related with quality of life, AED side effects, seizure severity, and behaviour.


Eligibility criteria: Inclusion Criteria:

* Young people aged 6-21 years with intractable epilepsy receiving antiepileptic drug polytherapy

Exclusion Criteria:

* None

Primary outcomes:
measure: Effect of reduction in anti-epileptic medications on quality of life in young people with intractable epilepsy
timeFrame: 6 months
Secondary outcomes:
measure: Identify other determinants of quality of life in this group of subjects
timeFrame: 6 months
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Neurosciences Unit, UCL Institute of Child Health, The Wolfson Centre,
Study officials:
References:
Clinical trial NCT00328822: Quetiapine for Primary Insomnia Patients : A Randomized Controlled Trial
Official title: Quetiapine for Primary Insomnia Patients : A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Primary Insomnia
Keywords: Primary insomnia
Quetiapine
Randomized controlled trial
Double blind
Lead sponsor: Khon Kaen University
Sponsor class: OTHER
First posted: 2006-05-22
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Primary insomnia patients will sleep with Quetiapine not better than without Quetiapine

Detailed description: 1. Primary insomnia will be diagnosed according to DSM-IV-TR
2. After consenting, cases will be divided (double blind randomization)in to two arms 2.1 sleep hygiene with placebo group 2.2 sleep hygiene with Quetiapine group
3. outcome measurement: sleep diary, sleep satisfaction visual analog scale and sleep satisfaction likert scale
4. statistical method: dependent T test

Eligibility criteria: Inclusion Criteria:

* Primary insomnia Patients by DSM-IV-TR criteria
* cases enrolled: age 18-65 educated

Exclusion Criteria:

* Currently receiving Quetiapine or other hypnotic drugs
* Liver disease
* Patients with heart Dz, Hypertension, thyroid disease
* History of epilepsy or febrile convulsion
* pregnant
* cognitive impairments
* History of Orthostatic Hypotension
* Patient with other Psychiatric conditions or Drug dependence

Primary outcomes:
measure: Total Sleep Time
timeFrame: 3 weeks
Secondary outcomes:
measure: Sleep Latency Period, Sleep satisfaction
timeFrame: 3 weeks
Other outcomes:
Locations:
city: Khon Kaen
country: Thailand
facility: Srinagarind Hospital, Khon Kaen University
Study officials:
affiliation: Department of Psychiatry, Faculty of Medicine, Khon Kaen University
name: Kanida Tassniyom, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Tassniyom K, Paholpak S, Tassniyom S, Kiewyoo J. Quetiapine for primary insomnia: a double blind, randomized controlled trial. J Med Assoc Thai. 2010 Jun;93(6):729-34.
Clinical trial NCT06830122: Effects of Lactobacillus Crispatus LCr86 on Bacterial Vaginosis and Ovarian Function in Women
Official title: Effects of Lactobacillus Crispatus LCr86 on Bacterial Vaginosis and Ovarian Function in Women: a Randomized, Double-blind, Placebo-controlled Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Patients With Bacterial Vaginosis
Lead sponsor: Wecare Probiotics Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2025-02-17
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Lactobacillus crispatus LCr86 was selected as a test preparation to observe its clinical efficacy in an intervention trial of combined antibiotic treatment and evaluate its effect on the cure rate, recurrence rate and vaginal flora of patients with bacterial vaginitis.


Eligibility criteria: Inclusion Criteria:

1. 18 to 65 years of age, history of sexual activity, premenopausal women;
2. Nugent score ≥ 7 for diagnosis of BV;
3. Signed informed consent.

Exclusion Criteria:

1. Mixed vaginitis, such as vulvovaginal candidiasis (VVC), Trichomonas vaginalis (TV) infection, Chlamydia trachomatis (CT) infection, or gonococcal vaginitis;
2. History of systemic organic or psychiatric disease;
3. Planned pregnancy, breastfeeding, or menstruation;
4. Have used any antibiotics within 5 days of disease onset;
5. Long-term use of contraceptives or immunosuppressants;
6. Hypersensitivity or allergy to known components of the study drug.

Primary outcomes:
measure: Cure rates for bacterial vaginitis
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05209022: Beetroot Juice Ingestion and Vertical Jump Performance
Official title: Acute Effects of Beetroot Juice Ingestion on Components of Vertical Jump Performance
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dietary Supplements
Lead sponsor: Universidad Francisco de Vitoria
Sponsor class: OTHER
Collaborators: name: Ankara University
name: University of Seville
First posted: 2022-01-26
Enrollment: 19
Sex: MALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Beetroot juice is a dietary supplement with good evidence for improving sports performance in different sport contexts, however, the evidence about the effects of beetroot juice in jump capacity is unclear. Thus, the aim of this study was to conduct a comprehensive examination of beetroot juice effects on vertical jump performance

Detailed description: Beetroot juice is a dietary supplement with good evidence for improving sports performance in different sport contexts, however, the evidence about the effects of beetroot juice in jump capacity is unclear. Therefore a deeper knowledge about the effects of beetroot juice on several components of vertical jump performance remain largely unexplored between we can mention phase duration peak power, average power, peak velocity, initial force, and peak force. Thus, the aim of this study was to conduct a comprehensive examination of beetroot juice effects on several countermovement jump components.

Eligibility criteria: Inclusion Criteria:

Experience in resistance training (at least 18 months of three weekly sessions).

A one-repetition maximum weight (1 RM) higher than bodyweight in the bench press and of 1.5 of body weight in squat exercise No sports supplement was taken in the previous three months No smoking. No cardiovascular, pulmonary or neurological disease. To not be considered an elite athlete.

Exclusion Criteria:

Age \<18 year or \> 35 years.

Primary outcomes:
measure: Jump height
timeFrame: 72-hours
measure: Peak Power
timeFrame: 72-hours
measure: Average power
timeFrame: 72-hours
Secondary outcomes:
measure: Peak velocity
timeFrame: 72-hours
measure: Phase durations
timeFrame: 72-hours
Other outcomes:
Locations:
city: Madrid
country: Spain
facility: Universidad Francisco de Vitoria
Study officials:
References:
Clinical trial NCT01519622: Impact of Disease on the Concept of End-of-life Decisions of the Elderly in the Community
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Sick Elderly
Keywords: End of life decisions
Perception of illness
Lead sponsor: Meir Medical Center
Sponsor class: OTHER
First posted: 2012-01-27
Enrollment: 88
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Community sample

Brief summary: The purpose of this study is to determine the priorities of the elderly in the community about end-of-life decisions. To check the perception of the disease in the elderly in the community.

Detailed description: This study is descriptive adapters which examines the relationship between illness perception and preferences of end of life decisions in the elderly in the community.

Population and sample: The target population will be elderly and healthy community elderly population was accessible due to a special branch of the club together in the center of the country. Sample to be a sample of convenience. The study will include 88 seniors aged 65 and over to get the power of 0.80 and alfa 0.05, Tools: The study used three tools.

* The first tool is a questionnaire on demographic and clinical details
* The second tool questionnaire the Long term support program (LTSP)
* The third tool is a questionnaire perception of the disease Revised Illness Perceptions Questionnaire (IPQR)

The research process:

Investigator will present the proposal to the Commissioner Fund hospitals and request approval for the study. After receiving approval from the director Department of Health fund the hospital will make data collection phase HMO, days and hours of reception. Interrogator he is to partition the questionnaires and will be present when filling out the questionnaires to help, if and created a situation of lack of understanding of the questionnaires. Scholar, came to the population for the Disabled arriving at the clinic visit, and introduce himself and the subject of research. investigator will indicate questionnaire is anonymous.

Eligibility criteria: Inclusion Criteria:

* Chronic illness
* Literate in Hebrew
* Treated in community HMO

Exclusion Criteria:

* Someone hospitalized in previous year
* History of mental illness
* Cognitive problems

Primary outcomes:
measure: Sick Elderly in the Community
timeFrame: One year
Secondary outcomes:
Other outcomes:
Locations:
city: Kfar Saba
country: Israel
facility: Meir Medical Center
Study officials:
References:
Clinical trial NCT06745622: Long-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria
Official title: A Multicenter, Open-label Study to Evaluate the Long-term Safety, Tolerability and Efficacy of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria（PNH）
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Paroxysmal Nocturnal Hemoglobinuria
Lead sponsor: Haisco Pharmaceutical Group Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2024-12-20
Enrollment: 47
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a multicenter, open-label study to evaluate the long-term safety, tolerability and efficacy of HSK39297. Adult patients with PNH who had previously received and completed HSK39297 study treatment will be included. Eligible subjects can maintain HSK39297 treatment until the end of the study.


Eligibility criteria: Inclusion Criteria:

1. Patients With PNH who have previously received and completed HSK39297 treatment , and According to the researchers' judgment, the benefits of treatment outweigh the risks and may benefit from continued treatment with HSK39297;
2. Understand the study procedures and methods, voluntarily participate in this trial.

Exclusion Criteria:

1. Hereditary or acquired complement deficiency;
2. Active primary or secondary immunodeficiency;
3. History of splenectomy, bone marrow/ hematopoietic stem cell or solid organ transplants;
4. History of recurrent invasive infections caused by encapsulated organisms( e.g. meningococcus or pneumococcus) or Mycobacterium tuberculosis;
5. History of serious comorbidities that have been determined to be unsuitable for participation in the study;
6. Pregnant or Lactating women.

Primary outcomes:
measure: Incidence and severity of adverse events
timeFrame: through study completion，about 2 years
Secondary outcomes:
measure: Proportion of participants achieving hemoglobin levels ≥ 12 g/dL in the absence of red blood cell transfusions
timeFrame: through study completion，about 2 years
measure: Change From Baseline in Hemoglobin in the absence of red blood cell transfusions
timeFrame: through study completion，about 2 years
measure: Proportion of participants who remain free from transfusions
timeFrame: through study completion，about 2 years
measure: Rate of breakthrough hemolysis (BTH)
timeFrame: through study completion，about 2 years
measure: Proportion of participants with Major Adverse Vascular Events (MAVEs)
timeFrame: through study completion，about 2 years
Other outcomes:
Locations:
city: Nanjing
country: China
facility: The First Affiliated Hospital of Nanjing Medical University
state: Jiangsu
Study officials:
References:
Clinical trial NCT03405922: Perianal Nerval Block in Proctological Interventions
Official title: Perianal Nerval Block in Proctological Interventions: a Prospective Randomized Double Blinded Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Perianal Fistula
Fissure in Ano
Hemorrhoids
Lead sponsor: University Hospital, Basel, Switzerland
Sponsor class: OTHER
First posted: 2018-01-23
Enrollment: 166
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to evaluate whether a local perianal block performed during a proctological intervention can reduce the postoperative pain.

Detailed description: The aim of this study is to evaluate whether a local perianal block performed during a proctological intervention can reduce the postoperative pain.

All patients will undergo surgery under general or spinal anesthesia. At the end of the surgery, the surgeon will perform a perianal block using the local anesthetic or the placebo upon randomisation. The experimental group will receive a local anesthetics and the control group a normal saline injection. All injections will be perianal, peripheral to the external anal sphincter.

Eligibility criteria: Inclusion Criteria:

* Patients with surgical indication for hemorrhoids, fistula-in-ano or anal fissures.
* Age of 18 or above

Exclusion Criteria:

* age under 18.
* Patients unable to understand an informed consent.
* Emergency operations
* Pregnant women.
* Patients with acute perianal infection.
* Patients allergic to any component of the local anesthetic

Primary outcomes:
measure: Postoperative Pain
timeFrame: 24 hours post-surgery
Secondary outcomes:
measure: Quality of Life assessed by questionnaire
timeFrame: 2 weeks post-surgery
Other outcomes:
Locations:
city: Basel
country: Switzerland
facility: St Claraspital
Study officials:
affiliation: St:Claraspital
name: Daniel Steinemann
role: PRINCIPAL_INVESTIGATOR
References:
citation: Rotigliano N, Fuglistaler I, Guenin MO, Dursunoglu GB, Freiermuth D, von Flue M, Steinemann DC. Perianal block with ropivacaine as a supplement to anaesthesia in proctological surgery: double-blind randomized placebo-controlled trial (PERCEPT). Br J Surg. 2020 Jul;107(8):960-969. doi: 10.1002/bjs.11520. Epub 2020 Mar 18.
Clinical trial NCT01293422: Effects of Pregnane X Receptor (PXR) Activation on Human Glucose, Lipid and Hormone Homeostasis
Official title: PXR-aktivaation Vaikutukset Sokeri-, Kolesteroli- ja Hormonitasapainoon
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Glucose Metabolism
Keywords: PXR, glucose, cholesterol
Lead sponsor: University of Oulu
Sponsor class: OTHER
First posted: 2011-02-10
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: This clinical trial is designed to study the effects of pregnane X receptor activator rifampicin on the glucose, lipid and hormone homeostasis in healthy volunteers. The main hypothesis is that rifampicin raises postprandial glucose studied with oral glucose tolerance test. The study is a non-randomized, one-phase, open-label trial. Twelve subjects will be given 600 mg of rifampicin a day for a week. The main outcome measures are the changes in the glucose and insulin levels during oral glucose tolerance test.


Eligibility criteria: Inclusion Criteria:

* Healthy volunteer
* Age 18-45 years
* Body mass index 19-28

Exclusion Criteria:

* Any continuous medication
* Any significant disease
* Allergy to rifampicin
* Pregnancy and breast feeding
* Fear of needles and previous difficult blood samplings
* Substance abuse
* Participation in another clinical drug trial within 1 month of enrollment
* Use of soft contact lenses

Primary outcomes:
measure: Glucose levels during oral glucose tolerance test
Secondary outcomes:
Other outcomes:
Locations:
city: Oulu
country: Finland
facility: Oulu University Hospital
Study officials:
affiliation: Oulu University Hospital
name: Janne Hukkanen, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Rahunen R, Kummu O, Koivukangas V, Hautajarvi H, Hakkola J, Rysa J, Hukkanen J. Pregnane X Receptor-4beta-Hydroxycholesterol Axis in the Regulation of Overweight- and Obesity-Induced Hypertension. J Am Heart Assoc. 2022 Mar 15;11(6):e023492. doi: 10.1161/JAHA.121.023492. Epub 2022 Mar 1.